Leap Therapeutics Reports Third Quarter 2023 Financial Results
/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...
Source: prnewswire.com
Defiance Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Defiance Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Defiance Study Today - Breaking & Trending Today
Leap Therapeutics Reports Second Quarter 2023 Financial Results
/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...
Source: prnewswire.com
Leap Therapeutics : Announces Completion of Enrollment in Part A of the DeFianCe Study of - Form 8-K
Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients Cambridge, MA -... | April 12, 2023
Source: marketscreener.com
Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...
Source: prnewswire.com
Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting
/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today...
Source: prnewswire.com